Sage Therapeutics Inc. diskutieren
Sage Therapeutics Inc.
WKN: A117WF / Symbol: SAGE / Name: SAGE / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
7,60 €
1,12 %
Sage Therapeutics, Inc. (NASDAQ: SAGE) was upgraded by analysts at Royal Bank of Canada from a "sector perform" rating to an "outperform" rating. They now have a $60.00 price target on the stock, up previously from $40.00.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $70.00 price target on the stock.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at TD Cowen from $105.00 to $28.00. They now have an "outperform" rating on the stock.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target raised by analysts at JPMorgan Chase & Co. from $24.00 to $29.00. They now have an "overweight" rating on the stock.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at JPMorgan Chase & Co. from $29.00 to $28.00. They now have an "overweight" rating on the stock.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) is now covered by analysts at Citigroup Inc.. They set a "sell" rating and a $8.00 price target on the stock.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at JPMorgan Chase & Co. from $28.00 to $23.00. They now have an "overweight" rating on the stock.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at JPMorgan Chase & Co. from $23.00 to $18.00. They now have an "overweight" rating on the stock.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Bank of America Co. from $11.00 to $6.00. They now have an "underperform" rating on the stock.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $26.00 price target on the stock, down previously from $52.00.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) had its price target lowered by analysts at Piper Sandler from $26.00 to $9.00. They now have an "overweight" rating on the stock.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) is now covered by analysts at Bank of America Co.. They set an "underperform" rating and a $5.00 price target on the stock.
Ratings data for SAGE provided by MarketBeat
Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at Wall Street Zen from a "hold" rating to a "sell" rating.
Ratings data for SAGE provided by MarketBeat
Neueste Beiträge
Citigroup_Inc_ in International Paper diskutieren